SEARCH

SEARCH BY CITATION

Summary

  1. Top of page
  2. Summary
  3. Does the epidemiological association occur by chance or by design?
  4. Are patients with HCV infection more insulin-resistant than those with other liver diseases?
  5. What are the mechanisms of altered insulin signalling by HCV?
  6. Is the association between diabetes and HCV infection clinically significant?
  7. Conclusion
  8. References

There is now consistent epidemiological evidence for an association between chronic hepatitis C and diabetes. Important, although so far limited longitudinal data, have documented an increased risk for diabetes in patients infected by hepatitis C virus (HCV) especially in those with metabolic risk factors such as a high BMI and older age. HCV encoded proteins might alter insulin signalling thus explaining impaired insulin sensitivity and the occurrence of glycaemic dysregulation even before the cirrhotic stage. The consequences of the association between diabetes and HCV infection are an increased liver fibrosis stage and faster fibrosis progression rate. This article reviews recent human and experimental data on the HCV-diabetes association.

Both hepatitis C and diabetes are common diseases with an estimated 160 million individuals infected by hepatitis C virus (HCV) worldwide and 120 million suffering from diabetes. Besides their considerable prevalence these two diseases seem to share little in common and yet recent data have suggested that their concurrent presence in some individuals may be higher than would be expected by chance alone. Certainly, advanced cirrhosis induces dysregulation of glycaemic control which may result in overt diabetes.1 However, this does not account for the bulk of data from numerous studies from liver clinics documenting a higher prevalence of diabetes among HCV patients than among controls. Other studies from patients followed for endocrine or haematological disorders confirmed the epidemiological association between chronic hepatitis C and type 2 diabetes.

This article will summarize some recent key data on the epidemiological association between these two conditions, their mechanisms and their clinical relevance. Excellent recent reviews are available for a more comprehensive report.2

Does the epidemiological association occur by chance or by design?

  1. Top of page
  2. Summary
  3. Does the epidemiological association occur by chance or by design?
  4. Are patients with HCV infection more insulin-resistant than those with other liver diseases?
  5. What are the mechanisms of altered insulin signalling by HCV?
  6. Is the association between diabetes and HCV infection clinically significant?
  7. Conclusion
  8. References

Two important studies performed in the general population have documented an increased prevalence of diabetes among patients infected with HCV.3, 4 The first is a multicentric cross-sectional survey in the United States involving 9822 individuals in whom the relative risk of being diagnosed with diabetes increased 3.8 times in the presence of HCV.3 Interestingly, although the association between HCV infection and type 2 diabetes was independent of age, sex, race, body mass index (BMI) and family history of diabetes, it was significant only in subjects older than 40. This suggests that although HCV infection might induce insulin resistance, the occurrence of overt diabetes necessitates additional factors such as the physiological resistance to insulin induced by ageing.

Because of its cross-sectional design the study by Mehta et al.4 cannot determine if there is a causal relationship behind the mere association between HCV infection and diabetes. Therefore, the only longitudinal study available thus far provides critical information in this regard. The same author studied a community-based cohort of 10 275 individuals who were free of diabetes at entry and were followed over a 9-year period. The incidence of diabetes was higher in individuals with HCV infection at entry, but here again, the excessive risk was significant only in older patients with a higher BMI. In this group of individuals with a high risk of diabetes development, those with HCV infection had 12 times more chance of developing diabetes during follow-up. Unfortunately, the prevalence of HCV infection was surprisingly low in this cohort (0.8% vs. 1.8% in the USA population) and thus the study could be underpowered for detecting the impact of HCV infection in patients at low risk for diabetes, namely in younger lean individuals. Nevertheless, the study provides valuable information showing that as HCV infection precedes the development of diabetes, a causal relationship is possible, at least in high-risk individuals.

By selecting individuals in the general population most of whom were presumed to be in good health, these community-based studies minimize the confounding contribution of liver disease per se in the development of diabetes. However, the possibility still exists that advanced liver disease induced by HCV (i.e. cirrhosis) accounts, non-specifically, for the association between HCV and diabetes. Several studies are now available showing that even HCV patients with chronic hepatitis but not cirrhosis have an increased prevalence of diabetes.5–7 Recently, Kawaguchi et al.7 showed higher serum insulin levels and higher homeostatis model assessment (HOMA) values in 158 Japanese patients with non-cirrhotic chronic hepatitis C than in 179 controls with diverse other liver diseases. This suggests that even before the cirrhotic stage, HCV infection induces insulin resistance that can predispose to the development of diabetes. Taking the matter one step further, Lecube et al.6 demonstrated a fourfold higher risk of diabetes and/or impaired fasting glucose in 498 non-cirrhotic HCV patients than in 144 non-cirrhotic patients with non-HCV-related chronic hepatitis. Moreover, in HCV patients, an oral glucose tolerance test was diagnostic of diabetes in 18% and of impaired glucose tolerance in 30%. As this was much higher than in the non-HCV population, the authors went recommended universal screening of glucose metabolic disorders in HCV patients. However, it is important to keep in mind that no study to date has matched HCV and control patients on the degree of liver fibrosis and therefore a higher proportion of bridging fibrosis in the HCV group than in the non-HCV group might account for these differences (see below).

Are patients with HCV infection more insulin-resistant than those with other liver diseases?

  1. Top of page
  2. Summary
  3. Does the epidemiological association occur by chance or by design?
  4. Are patients with HCV infection more insulin-resistant than those with other liver diseases?
  5. What are the mechanisms of altered insulin signalling by HCV?
  6. Is the association between diabetes and HCV infection clinically significant?
  7. Conclusion
  8. References

If the epidemiological association holds true and if HCV contributes to the occurrence of diabetes even in patients without cirrhosis, then HCV-infected patients should display higher levels of insulin resistance. Several studies are now available comparing surrogate markers of insulin resistance in HCV-infected and non-HCV patients.7–9 Most, but not all,8 have demonstrated higher fasting insulin serum levels and higher HOMA indices in HCV than in non-HCV patients. However, this type of comparison is meaningful only if cases and controls are carefully matched, not only on anthropometric risk factors for diabetes (age, sex, BMI) but also for the degree of liver injury, mainly the fibrosis stage. Indeed, Petit et al. made the important observation in HCV patients that increasing levels of fibrosis are associated with increasing insulin resistance as evaluated by the HOMA model.10Subsequently this observation has been largely confirmed.7–9 One study in particular has shown that HCV patients have higher levels of insulin resistance and of hyperinsulinaemia than controls with primary biliary cirrhosis, even after adjustment for age, sex and BMI and when considering only patients with no or minimal fibrosis.9

What, then, causes hyperinsulinaemia in HCV-infected individuals? A first explanation could be that the hepatic insulin extraction is impaired either because of advanced liver disease or because of coexisting steatosis,11–13 and therefore higher systemic levels of insulin are simply the result of reduced hepatic clearance. This, however, has been ruled out by the demonstration that hepatic insulin extraction, as assessed by the C-peptide/insulin ratio, was similar between HCV and non-HCV patients.14 An alternative explanation could be that liver injury, irrespective of its cause, induces insulin resistance, for instance through cytokines such as tumour necrosis factor (TNF)-α and/or interleukin (IL)-6 which are induced during liver inflammation and/or fibrosis. Hickman et al. argue against this possibility by demonstrating that while there is a correlation between insulin levels and fibrosis stages in overweight HCV patients, no such correlation exists in lean individuals.8 Therefore it appears that, at least in HCV patients, hyperinsulinaemia is not a non-specific effect of progressing liver injury. A third possibility would be that HCV induces insulin resistance by interfering with insulin signalling. Recently, several human and experimental studies have given credit to this theory.

What are the mechanisms of altered insulin signalling by HCV?

  1. Top of page
  2. Summary
  3. Does the epidemiological association occur by chance or by design?
  4. Are patients with HCV infection more insulin-resistant than those with other liver diseases?
  5. What are the mechanisms of altered insulin signalling by HCV?
  6. Is the association between diabetes and HCV infection clinically significant?
  7. Conclusion
  8. References

Insulin signalling is initiated upon binding to a specific receptor, the insulin receptor, which is expressed in target cells and has a tyrosine kinase activity. This results in the phosphorylation of tyrosine residues of insulin receptor substrate (IRS) proteins, especially IRS-1 and IRS-2, which play a crucial role in the regulation of the multiple growth and metabolic effects of insulin. Upon tyrosine phosphorylation, IRS starts recruiting additional adapter and signalling molecules, resulting in the activation of second messenger cascades.15, 16 One such molecule is phosphatidylinositol 3-kinase (PI3-kinase) and its downstream effector, Akt which control many of the metabolic effects of insulin.17

Aytug et al. first reported impaired IRS-1/PI3-kinase signalling in patients with HCV infection.18 They demonstrated reduced tyrosine phosphorylation of IRS-1 in liver tissue of patients with HCV infection compared to controls with non-viral liver disease. This was accompanied by a significant decrease in insulin-stimulated PI3-kinase activity and a severely blunted Akt phosphorylation. Further confirmation of this important study is eagerly awaited.

Two important sets of experimental data confirm these human findings and demonstrate that the core protein of HCV are responsible for these effects. Kawaguchi et al. performed elegant in vitro studies demonstrating that the core protein of HCV reduces IRS-1 and IRS-2 expression with resulting inhibition of insulin signalling through the PI3-kinase pathway and reduced Akt-dependent metabolic effects.7 The reduction in IRS-1 and -2 expression was the result of the induction by the core protein of SOCS3, which in turn promotes proteosomal degradation of IRS-1 and -2 through ubiquitination.7 Working with transgenic mice for the HCV core protein, Shintani et al. demonstrated in vivo that overexpression of the core protein induces hepatic insulin resistance.19 Indeed, HCV core transgenic mice compared with wild-type animals displayed high serum insulin levels and impaired inhibition of hepatic glucose output in response to insulin. Remarkably, these changes were documented at a young age, before the occurrence of steatosis which by itself could cause insulin resistance.20, 21 This hepatic insulin resistance precipitated the occurrence of overt diabetes upon feeding the mice a high fat diet. Expression of the core protein transgene resulted in altered tyrosine phosphorylation of IRS-1 (but not IRS-2) and increased hepatic expression of TNF-α, two possible reasons why these mice developed insulin resistance. In vivo antagonism of TNF-α by systemic administration of anti-TNF-α antibodies restored insulin sensitivity and tyrosine phosphorylation of IRS-1.19 Data in humans are thus far limited but preliminary results suggest that the level of circulating HCV core antigen correlates with hyperinsulinaemia in HCV patients.7

However, enticing all these models might be, they do not entirely accommodate the available data on differential tissue distribution and function of individual IRS. Indeed, the liver does not appear to be the main target of IRS-1 because glycogen synthesis and hepatic glucose output are mainly regulated by IRS-2.22 Moreover, IRS-1 deficiency through genetic inactivation is very effectively compensated by IRS-2, at least in the liver.23 Thus, additional data are needed before drawing firm conclusions on the mechanisms and intermediaries of HCV-induced insulin resistance.

Is the association between diabetes and HCV infection clinically significant?

  1. Top of page
  2. Summary
  3. Does the epidemiological association occur by chance or by design?
  4. Are patients with HCV infection more insulin-resistant than those with other liver diseases?
  5. What are the mechanisms of altered insulin signalling by HCV?
  6. Is the association between diabetes and HCV infection clinically significant?
  7. Conclusion
  8. References

Several studies have now documented the deleterious impact of insulin resistance on liver injury. Insulin resistance as measured by the HOMA model has a significant albeit rather modest contribution to fibrosis stage and fibrosis progression9, 24 which is independent of age and genotype.9 Interestingly this holds true even before the cirrhotic stage.9 As stated above, high serum insulin levels are also associated with increasing fibrosis stages,24 at least in overweight patients.8 High serum glucose has been recognized as an independent predictor of liver fibrosis even after adjustment for age, sex and alcohol consumption.25 Its profibrogenic effect is stronger and independent from that of the BMI and again, is noticeable even before the cirrhotic stage.25 Finally, several studies have also documented that overt diabetes is independently associated with more severe fibrosis in patients with chronic hepatitis C.26, 27

The association of insulin resistance to fibrosis raises nevertheless other interesting questions. One of them is what are the mechanisms explaining increased fibrogenesis in insulin-resistant states?28 While there are no definitive answers, certain hypotheses are worth pursuing in future studies. Insulin resistance could contribute to a chronic inflammatory state at the tissue level with resultant expression of proinflammatory cytokines such as TNF-α.29 Alternatively, hyperinsulinaemia can induce proliferation of hepatic stellate cells30 and high levels of glucose induce the expression of connective tissue growth factor,31 a strongly profibrogenic cytokine. Another relevant mechanism is related to the presence of advanced glycated end products (AGE). These are the result of glycosylation of a large number of serum proteins induced by long-standing hyperglycaemia. Receptors for AGE have been demonstrated on the cell membrane of hepatic stellate cells and ligand-induced activation of these receptors triggers the myofibroblastic activation of quiescent stellate cells.32

Another important question is that regarding the relative contribution of steatosis per se vs. that of insulin resistance in the genesis and progression of liver fibrosis. Obviously these two conditions are linked and recognizing their specific contributions is difficult. Almost all studies have documented an association between steatosis and fibrosis by univariate analysis28 and some have suggested a relation between steatosis worsening and fibrosis progression.33 Experimental data have demonstrated the activation of profibrogenic pathways in the presence of steatosis.34–36 However, the role of steatosis may not be direct and may be confounded by the underlying insulin resistance.37 Indeed, after taking into account all measurable risk factors of insulin resistance the independent association between steatosis and fibrosis is no longer significant in some studies.9, 25, 38

Conclusion

  1. Top of page
  2. Summary
  3. Does the epidemiological association occur by chance or by design?
  4. Are patients with HCV infection more insulin-resistant than those with other liver diseases?
  5. What are the mechanisms of altered insulin signalling by HCV?
  6. Is the association between diabetes and HCV infection clinically significant?
  7. Conclusion
  8. References

This is an era of fascinating discoveries of the complex interplay between the virus and host metabolic pathways. The association between HCV infection and type 2 diabetes is real and appears to be causally linked, at least in predisposed individuals (older and overweight). The virus itself, and not the liver disease may be the culprit by interfering with insulin signalling. As a consequence, patients with HCV infection appear to be more insulin-resistant than those with other types of liver disease, even after adjusting for the stage of fibrosis. Clinically, long-standing insulin resistance, hyperglycaemia and diabetes may worsen liver fibrosis. Whether it also reduces the efficacy of anti-viral treatment remains to be studied but this may be the case as overweight and steatosis are associated with a lower response.39–41 Preliminary data suggest that correction of insulin resistance might help achieve higher response rates with anti-viral treatment.42, 43

References

  1. Top of page
  2. Summary
  3. Does the epidemiological association occur by chance or by design?
  4. Are patients with HCV infection more insulin-resistant than those with other liver diseases?
  5. What are the mechanisms of altered insulin signalling by HCV?
  6. Is the association between diabetes and HCV infection clinically significant?
  7. Conclusion
  8. References
  • 1
    Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 61627.
  • 2
    Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 58697.
  • 3
    Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 5929.
  • 4
    Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 506.
  • 5
    Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 3559.
  • 6
    Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004; 27: 11715.
  • 7
    Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499508.
  • 8
    Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003; 39: 10428.
  • 9
    Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Gastroenterology 2003; 125: 1695704.
  • 10
    Petit J-M, Bour J-B, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: 27983.
  • 11
    Nygren A, Adner N, Sundblad L, Wiechel KL. Insulin uptake by the human alcoholic cirrhotic liver. Metabolism 1985; 34: 4852.
  • 12
    Kruszynska YT, Home PD, McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology 1991; 14: 10311.
  • 13
    Kaser S, Foger B, Waldenberger P, et al. Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis. J Hepatol 2000; 33: 9026.
  • 14
    Delgado-Borrego A, Casson D, Schoenfeld D, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77: 70310.
  • 15
    Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799806.
  • 16
    Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000; 106: 1659.
  • 17
    Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 16557.
  • 18
    Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 138492.
  • 19
    Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 8408.
  • 20
    Kim JK, Fillmore JJ, Chen Y, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001; 98: 75227.
  • 21
    Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 30238.
  • 22
    Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001; 15: 2099111.
  • 23
    Kido Y, Burks DJ, Withers D, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000; 105: 199205.
  • 24
    Maeno T, Okumura A, Ishikawa T, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2003; 18: 135863.
  • 25
    Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T for the LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 104955.
  • 26
    Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003; 98: 206471.
    Direct Link:
  • 27
    Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 72936.
  • 28
    Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 2004; 6: 229.
  • 29
    Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta. Science 2001; 293: 16737.
  • 30
    Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 174351.
  • 31
    Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 73844.
  • 32
    Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 2001; 34: 94352.
  • 33
    Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 28892.
  • 34
    Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis leads to in vivo lipid peroxydation in mice. J Hepatol 1996; 24: 2008.
  • 35
    Reeves HL, Burt AD, Wood S, Day CP. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996; 25: 67783.
  • 36
    Walsh MJ, Vanags DM, Clouston AD, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004; 39: 12308.
  • 37
    Ratziu V, Saboury M, Poynard T. Worsening of steatosis and fibrosis progression. Gut 2003; 52: 13867.
  • 38
    Asselah T, Boyer N, Guimont MC, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003; 52: 163843.
  • 39
    Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 7585.
  • 40
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 41
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 42
    Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 8994.
  • 43
    Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 4139.